Opteev Develops World's First Multiplex Biochip That Precisely Identifies COVID, Flu, RSV, and Respiratory Pathogens in Under 1 Minute

BALTIMORE, July 31, 2023 /PRNewswire/ — Opteev Technologies, Inc., a pioneering technology company at the forefront of diagnostics, has filed a patent (Patent Application #63/513,007) for a revolutionary multiplex biochip for respiratory infection diagnostics. The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute. This game-changing technology paves the way for an ultra-rapid, portable, and accurate syndromic diagnostic device to empower healthcare providers with immediate results at their fingertips.

The tiny biochip can directly detect whole viruses in real-time in both processed and unprocessed samples such as saliva or nasal swab and has demonstrated an unprecedented accuracy rate of 99.49% with an impressive limit of detection in its analytical performance evaluation. Furthermore, the biosensor achieves fine-tuned specificity by carefully selecting specific virus-binding peptides, enabling accurate identification of target viruses in complex samples. To ensure precise and reliable virus detection, the biochip utilizes artificial intelligence to optimize the frequency range effectively mitigating the impact of interfering noise signals.

Unlike conventional respiratory panels that cost tens of thousands of dollars and take days to provide results, Opteev’s multiplex biochip will offer healthcare providers affordable syndromic testing with the ability to process samples at the point of care, allowing for the simultaneous detection and specific identification of multiple pathogens instantaneously. This breakthrough technology will eliminate the need for speculation by providing healthcare providers with the critical information needed to deliver the most effective treatment options at the point of care.

“With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics,” said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies. “The potential of this technology to transform patient care, streamline operations, and reduce costs is truly remarkable.”

As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company welcomes potential collaborations and partnerships to further develop and commercialize its multiplex biochip. “Together, we can shape the future of diagnostics and unlock the massive potential of our game-changing multiplex biochip,” said Conrad Bessemer, Opteev’s Chairman and Co-founder.

For more information about Opteev Technologies and its groundbreaking multiplex biochip, please visit www.opteev.com.

About Opteev

Opteev Technologies, Inc., headquartered in Baltimore, MD, is a pioneering technology company at the forefront of diagnostics. With a strong focus on respiratory pathogen detection, Opteev is committed to developing innovative solutions that revolutionize the field of point-of-care diagnostics. As a subsidiary of Novatec, Inc., a trusted manufacturer and supplier of machinery and sensor technology, Opteev leverages decades of experience to drive advancements in healthcare.

Media Contact:

Dana Gardner

Vice President

[email protected]

Phone: 443-457-5214